Press Release: Agenus : Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral
Read full article »
Agenus is a Massachusetts-based biotechnology company that researches and commercializes immunotherapies for the treatment of cancer.
Read more